> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Priority Review for Amryt Oleogel-S10
- URL: https://www.fdaweb.com/fda-priority-review-for-amryt-oleogel-s10/
- Published: 2021-06-03T12:00:00.000Z
- Updated: 2026-09-14T17:01:35.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5149464

FDA has granted priority review for an Amryt NDA for oleogel-S10 to treat epidermolysis bullosa. The agency previously granted the treatment fast track designation and rare pediatric disease designation.

Amryt [says](https://www.marketwatch.com/press-release/fda-grants-priority-review-for-new-drug-application-for-oleogel-s10-for-the-treatment-of-epidermolysis-bullosa-2021-06-03?tesla=y&ref=fdaweb.com) oleogel-S10 is a potential treatment for the cutaneous manifestations of junctional and dystrophic epidermolysis bullosa, a rare genetic skin disorder affecting young children and adults for which there is no approved treatment.